Patent ID: 11857548
Assignee: BOW RIVER LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating mantle cell lymphoma (MCL), Waldenström's macroglobulinemia (WM), marginal zone lymphoma (MZL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), or chronic graft versus host disease (cGVHD) in a patient in need thereof with an anti-neoplastic drug, wherein the patient is treated with a strong CYP3A4 inhibitor, comprising:
a. discontinuing the strong CYP3A4 inhibitor treatment;
b. delaying administering, for at least about 3 days after discontinuing the strong CYP3A4 inhibitor treatment, a dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor; and then
c. administering the dose of the anti-neoplastic drug that the patient would have received based on the patient's age and condition if the patient had not been treated with the strong CYP3A4 inhibitor;
wherein the strong CYP3A4 inhibitor is posaconazole.